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Purpose: Hyperhomocyst(e)inaemia is an important risk factor for atherosclerosis, which is currently a major cause of death
in renal transplant patients. The aim of this study was to assess the influence of immunosuppressive therapy on homocyst(e)inemia
in renal transplant recipients.
Methods: Total serum homocysteine (by high performance liquid chromatography), creatinine, lipid profile, folic acid (by
radioimmunoassay—RIA) and vitamin B12 (by RIA) concentrations were measured in 3 groups. Group I patients (n=20) were
under treatment with cyclosporine, azathioprine, and prednisone; group II (n=9) were under treatment with azathioprine and prednisone;
and group III (n=7) were composed of renal graft donors for groups I and II. Creatinine, estimated creatinine clearance, cyclosporine
trough level, lipid profile, folic acid, and vitamin B12 concentrations and clinical characteristics of patients were assessed with the
aim of ascertaining determinants of hyperhomocyst(e)inemia.
Results: Patient ages were 48.8 ± 15.1 yr (group I), 43.3 ± 11.3 yr (group II); and 46.5 ± 14.8 yr (group III). Mean serum
homocyst(e)ine (tHcy) concentrations were 18.07 ± 8.29 mmol/l in renal transplant recipients; 16.55 ± 5.6 mmol/l and 21.44 ± 12.1
mmol/l respectively for group I (with cyclosporine) and group II (without cyclosporine) (NS). In renal donors, tHcy was significantly
lower (9.07 ± 3.06 mmol/l; group I + group II vs. group III, p<0.008). There was an unadjusted correlation (p<0.10) between age
(r=0.427; p<0.005) body weight (r=0.412; p<0.05), serum creatinine (r=0.427; p<0.05), estimated creatinine clearance (r=0.316;
p<0.10), and tHcy in renal recipients (group I +II). Independent regressors (r2=0.46) identified in the multiple regression model were
age (coefficient= 0.253; p=0.009) and serum creatinine (coefficient=8.07; p=0.045). We found no cases of hyperhomocyst(e)inemia
in the control group. In contrast, 38% of renal recipients had hyperhomocyst(e)inemia: 7 cases (35%) on cyclosporine and 4 (45%)
without cyclosporine, based on serum normal levels.
Conclusions: Renal transplant recipients frequently have hyperhomocyst(e)inemia. Hyperhomocyst(e)inemia in renal transplant
patients is independent of the scheme of immunosuppression they are taking. The older the patients are and the higher are their
serum creatinine levels, the more susceptible they are to hyperhomocyst(e)inemia following renal transplantation.
DESCRIPTORS: Homocysteine. Renal transplantation. Cyclosporine. Azathioprine. Prednisone.
Homocysteine is a sulfur-contain-
ing amino acid formed from methion-
ine metabolism. Hyperhomocyst(e)
inemia is an independent risk factor for
the development of atherosclerosis1,2.
In 1969, McCully described exten-
sive arterial thrombosis and atheroscle-
rosis in 2 children, establishing the
linkage between homocysteine and
vascular disease3. Since then, many re-
ports have reaffirmed this link-
age1,2,4,5,6,7,8,9,10,11,12. But it was only in
1994 that cardiovascular disease was
correlated with hyperhomocyst(e)
inemia in renal transplant patients13.
Efforts to identify factors known to in-
fluence homocysteine metabolism suc-
ceeded; however, although homocys-
teine concentrations can be success-
fully modulated with treatment14,15, we
do not yet know the influence of such
modulation on cardiovascular disease.
Immunosuppression after renal
transplantation potentially could en-
hance hyperhomocyst(e)inemia – and
its future modulation prevent it. We
tested the former hypothesis – that im-
munosuppression after renal transplan-
tation would enhance hyperhomo-
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cyst(e)inemia – in a cross-sectional
study on three groups of patients di-
vided according to presence or absence
of cyclosporine in the treatment regi-
men. We have also assessed the factors
known to influence homocysteine me-
tabolism in this population.
SUBJECTS AND METHODS
Fasting blood samples were col-
lected for analysis of total homocys-
teine (tHcy) by high-performance liq-
uid chromatography with fluorescence
detection. Normal serum total ho-
mocysteine concentration values
ranged from 5.5 to 17 mmol/l.
Plasma folate and vitamin B12 lev-
els were measured by radioimmunoas-
say. Serum creatinine, total cholesterol,
LDL cholesterol (low-density lipopro-
tein), HDL cholesterol (high-density
lipoprotein), and triglycerides were de-
termined using standard automated
clinical chemistry laboratory tech-
niques. Creatinine clearance was esti-
mated from the Cochkcroft-Gault for-
mula16. Whole blood cyclosporine
through levels were analyzed with TDx
Immunosuppressant Drug Assays –
Cyclosporine Monoclonal Whole
Blood (Abbot Laboratories).
Twenty-nine renal transplant pa-
tients were studied at least 12 months
after transplantation, undergoing treat-
ment with fixed doses of immunosup-
pressive drugs for 6 months and hav-
ing serum creatinine levels of less than
2.0 mg/dl. Study patients were not un-
der treatment with any vitamin supple-
ment following the transplantation.
End-stage renal disease was due to
chronic glomerulonephritis (n=11),
chronic pyelonephritis (n=5), nephro-
sclerosis (n=5), diabetic nephropathy
(n=3), polycystic kidney disease (n=2)
or undetermined cause (n=3).
Patients were divided into 2 groups
according to immunosuppression
therapy:
Group I: 20 renal transplant pa-
tients on cyclosporine, azathioprine,
and prednisone;
Group II: 9 renal transplant patients
on azathioprine and prednisone;
And the third group enrolled com-
prised renal donors (control group):
Group III: 7 renal graft donors for
groups I and II.
Results were expressed as mean ±
standard deviation (SD). Continuous
variables were compared by t-test, and
the chi-square test was applied for es-
timating the occurrence of categorical
variables. Pearson Product Moment
correlation was used for unadjusted
correlation between continuous vari-
ables. Multiple regression analysis was
performed to identify independent pre-
dictors of tHcy. Statistical significance
was defined as tests with a probability
of < 0.05. The statistical analyses were
performed in SigmaStat 2.0 software.
RESULTS
Characteristics of patients and con-
trol groups are summarized in Table 1.
The mean plasma homocyst(e)
inemia concentration was 18.07 ± 8.29
mmol/l in renal transplant recipients:
16.55 ± 5.6 mmol/l (group I, with
cyclosporine), and 21.44 ± 12.1 mmol/
l (group II, without cyclosporine)
(NS).In renal donors, tHcy was signifi-
cantly lower (9.07 ± 3.06 mmol/l;
group I + group II vs. group III,
p<0.008).
Pearson correlation was tested us-
ing age, body weight, dialysis duration
before transplantation, transplant dura-
tion, serum creatinine, estimated crea-
tinine clearance, cholesterol, HDL –
cholesterol and LDL – cholesterol, trig-
Table 1 - Clinical and laboratorial characteristics of renal transplant patients and control groups.
Group I Group II Group III
n 20 9 7
Age (yr; mean + SD) 48.8 ± 15.1 43.3 ± 11.3 46.5 ± 14.8
Sex (number female) 7 2 6
Serum creatinine (mg/dl; mean + SD) 1.18 ± 0.26 1.33 ± 0.44 0.97 ± 0.18
Body weight (Kg; mean + SD) 72.5 ± 16.8 66.8 ± 11.9 __________
Estimated creatinine clearance (ml/min ; mean + SD) 73.2 ± 25.1 69.5 ± 20.1 __________
Transplant duration (months; mean + SD) 49.4 ± 28.2 58.2 ± 18.2 __________
Dialysis duration before transplantation (months; mean + SD) 32.4 ± 25.5 39.8  ± 13.3 __________
tHcy (micromol/l; mean + SD) 16.5 ± 5.6 21.4 ± 12.1 9.1 ± 3.0 **
Folate (ng/ml; mean + SD) 7.7 ±  3.5 7.4  ± 1.2 6.7 ± 1.6 **
Vitamin B12 (pg/ml; mean + SD) 315.0 ± 139.1 418.0 ± 397.0 350.0 ± 176.5
Triglicerides (mg/dl; mean + SD) 219.4 ± 115.3 154.2 ± 103.3 129.7 ± 64.2
Cholesterol (mg/dl; mean + SD) 227.8 ± 40.9 183.8 ± 29.3 * 194.4 ± 36.7
HDL-cholesterol (mg/dl; mean + SD) 51.5 ± 11.4 54.0 ± 12.0 50.1 ± 5.3
LDL-cholesterol (mg/dl; mean + SD) 144.0 ± 43.1 105.7 ± 16.7 * 116.2 ± 34.1
*  p< 0.05 group I vs. group II
** p< 0.05 group I + II vs. group III
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lycerides, folate level, vitamin B12
level, azathioprine, and prednisone
doses vs. homocyst(e)inemia. Unad-
justed correlations (p<0.10) were
found between age (r=0.427; p<0.005),
body weight (r=0.412; p<0.05), serum
creatinine (r=0.427; p<0.05), estimated
creatinine clearance (r=0.316; p<0.10),
and tHcy in renal recipients (group I
+II). There was no statistically signifi-
cant correlation between sex and tHcy.
Independent regressors (r2=0.46) iden-
tified in the multiple regression model
were age (coefficient= 0.253; p=0.009)
and serum creatinine (coefficient=8.07;
p=0.045).
Total serum homocysteine in the
cyclosporine-treated group had no one
independent regressor in this study,
when age, body weight, dialysis dura-
tion before transplantation, transplant
duration, serum creatinine, cyclosporine
trough level, estimated creatinine clear-
ance, cholesterol, HDL-cholesterol and
LDL-cholesterol, triglycerides, folate
level, vitamin B12 level, azathioprine
dose, prednisone dose, and cyclosporine
dose were included.
We found no cases of
hyperhomocyst(e)inemia in the control
group. In contrast, 38% of renal recipi-
ents had hyperhomocyst(e)inemia: 7
cases (35%) in the cyclosporine-treated
group and 4 (45%) in the group not re-
ceiving cyclosporine, based on plas-
matic normal levels. If there was a posi-
tive and direct relationship between se-
rum and plasma homocysteine levels,
we would state, based on the Kang et
al. classification12, that for patients re-
ceiving cyclosporine, 35% had moder-
ate hyperhomocyst(e)inemia; for pa-
tients not receiving cyclosporine (group
II), 33% had moderate and 12% had in-
termediate hyperhomocyst(e) inemia.
DISCUSSION
Homocysteine is a sulfur-contain-
ing non-essential amino acid that is
formed as a product of methionine me-
tabolism. Its chemical structure is 2-
amin-4-mercaptobutanoic acid.
Methionine is converted to ho-
mocysteine through S-adenosyl me-
thionine. Then homocyst(e)ine under-
goes either remethylation or trans-
sulfuration. In the remethylation path-
way, homocysteine is salvaged by the
acquisition of a methyl group in a re-
action catalyzed by methionine syn-
thase. Vitamin B12 (cobalamin) is the
precursor of methylcobalamin, which
is the cofactor for methionine synthase,
and N5- methyl-tetrahydrofolate is the
methyl donor in this reaction.
Remethylation can also be catalyzed by
betaine-homocysteine methyl trans-
ferase17,18,19,20,21,22,23,24,25,26.
Under conditions in which an ex-
cess of methionine is present or cys-
teine synthesis is required, homocys-
teine condenses with serine to form
cystathionine in a reaction catalyzed by
the vitamin-B6-dependent enzyme,
cystathionine β-synthase17,18,19,20,22,24,25.
Cystathionine is subsequently hydro-
lyzed to form α-ketobutyrate and cys-
teine, which may in turn be incorpo-
rated into glutathione or further me-
tabolized to sulfate and excreted in the
urine18,26.
Clinical studies involving ho-
mocysteine generally rely on the mea-
surement of total plasma homocys-
teine, which includes homocysteine,
mixed disulfides involving homocys-
teine, homocysteine thiolactone, free
homocysteine, and protein-bound ho-
mocysteine17,27. The sum of all free and
protein-bound forms is referred as to-
tal homocysteine (tHcy) or as
homocyst(e)ine to emphasize the un-
certain distribution of reduced sulfhy-
dryl and oxidized disulfide moieties28.
This correct but cumbersome conven-
tion is frequently overlooked but needs
to be acknowledged17. Normal total
plasma homocysteine concentration
ranges from 5 to 15 mmol per liter in
the fasting state22, and serum levels are
known to be higher29,30 in the fasting
state. Kang et al. have classified
hyperhomocyst(e)inemia as moderate
(from 15 to 30 mmol per liter), inter-
mediate (> 30 to 100 mmol per liter),
and severe (>100 mmol per liter) on
the basis of fasting plasma measured
concentrations12. An oral challenge
(100 mg/kg) can be given to persons
suspected of hyperhomocyst(e)inemia
who have normal fasting
homocyst(e)ine levels. Plasma
homocyst(e)ine concentrations are de-
termined before methionine challenge
and 4 and 8 hours afterwards.
Hyperhomocyst(e)inemia is considered
to be present if the concentration of
tHcy is more than 2 standard deviations
above the mean11. The oral methionine
challenge is more useful for subjects
with cystathionine-β–synthase defi-
ciency than for those with
methylenetetrahydrofolate reductase
deficiency4,20.
There are genetic and acquired
causes of homocyst(e)inemia. Rare in-
born errors of metabolism result in ele-
vation of plasma and urine homocys-
teine. The homozygous deficiency of
cystathionine β-synthase is the most
common cause and is associated with
plasma tHcy levels up to 400 mmol per
liter 20. Atherothrombotic complications
frequently develop in young adulthood
and are often fatal9. Heterozygotes
typically have plasma levels in the
range of 20 to 40 mmol per liter1,4. A
homozygous deficiency of N5-N10-
methylene-tetrahydrolfolate reductase
(MTHFR) carries a much worse prog-
nosis, in part due to the complete lack
of effective therapy20. Kang et al. re-
ported a more common genetic defect
that is phenotypically expressed as a
thermolabile form of MTHFR that has
a prevalence of 5% in the general
population and 17% among patients
with coronary disease31,32. Deficiencies
in vitamin cofactors required for ho-
mocysteine metabolism, like folate, vi-
tamin B12, and B6, may promote
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hyperhomocyst(e)inemia, and supple-
mentation can normalize concentra-
tions of homocysteine14,15,21,33,34. Nega-
tive correlations have been related be-
tween folate, cobalamin, and
tHcy1,6,35,36,37,38,39,40,41. Several drugs can
interfere with the metabolism of ho-
mocysteine such as methotrexate,
phenytoin, and theophylline20.
In spite of in vitro studies report-
ing renal metabolism of homocysteine,
and in vivo studies in which the con-
centration of homocysteine in the
plasma of rats was increased due to its
substantial uptake and metabolism by
the kidney42,43,44, van Guldener et al.
showed no net renal extraction of ho-
mocysteine in fasting humans45,46.
These findings rekindle a search for
“uremia-induced” extrarenal defects in
homocysteine metabolism18. Although
it was said that urinary homocysteine
excretion was minimal42, hyper-
filtrating diabetic subjects with super-
normal glomerular filtration rates may
have subnormal fasting tHcy levels47.
Indeed, it should be stressed that glom-
erular filtration rate and cystatin C are
independent determinants of tHcy, and
they are much better determinants than
is creatinine concentration48,49. Al-
though there is a direct relationship be-
tween tHcy and KT/V (an index of di-
alysis adequacy), the dialytic amount
of tHcy did not seem to contribute sig-
nificantly to its removal38.
In 1969, McCully described promi-
nent arterial damage in patients with a
deficiency in methionine metabolism
and homocysteinemia and hypoth-
esized that homocysteine derivatives
played a role in the pathogenesis of
atherosclerosis3. Histopathologic hall-
marks of homocysteine-induced vascu-
lar injury include intimal thickening,
elastic lamina disruption, smooth
muscle hypertrophy, marked platelet
accumulation, and the formation of
platelet-enriched occlusive thrombi3,5.
The postulated effects involve oxida-
tive damage to vascular endothelial
cells and increased proliferation of vas-
cular smooth cells after oxidative me-
tabolism of homocysteine to homocys-
tine and homocysteine thiolactone.
Oxidative modification of low-density
lipoprotein (LDL) promotes the forma-
tion of foam cells, which in turn yields
another source of reactive species50. A
direct endothelial cell injury can also
occur51. It seems that prostacyclin pro-
duction is unlikely to result from ho-
mocysteine effects52,53,54. Prolonged ex-
posure of endothelial cells to homocys-
teine impairs production of nitric ox-
ide55 and alters the normal
antithrombotic phenotype of the endot-
helium by attenuation of endothelial
cell tissue-plasminogen-activator bind-
ing sites56,57, activation of factor V58,
inhibition of protein59,60 and heparan
sulfate6 and decreasing endothelial
antithrombotic activity due to changes
in thrombomodulin function60.
There is abundant epidemiological
evidence of the association between
hyperhomocyst(e)inemia and athero-
thrombosis either in normal or end-
stage renal failure popula-
tion1,2,46,7,8,9,10,11,12.
Patient death from cardiovascular
causes is an important reason for trans-
plant failure over time62. Fifty to sixty
percent of deaths are directly attribut-
able to cardiovascular disease. Future
advances in long-term renal graft sur-
vival will depend largely on the success
of preventing myocardial infarction
and death in this patient population63.
Renal transplant recipients are
prone to atherosclerotic complications,
and risk factors independently associ-
ated in a multivariate analysis after ac-
counting for pretransplant vascular dis-
ease were: increasing patient age, dia-
betes mellitus, male gender, cigarette
smoking, hypertension, and elevated
serum cholesterol levels. The data had
also suggested that an increased preva-
lence of known risk factors explains
the high incidence of cardiovascular
disease in the renal transplant recipi-
ent64. Immunosuppressive drugs that
prevent allograft rejection could exac-
erbate atherosclerosis. However, this
possibility could not explain all cases,
so efforts were made to identify other
risk factors.
 Fasting hyperhomocyst(e)inemia is
an independent risk factor for coronary
artery disease, stroke, peripheral vascu-
lar atherosclerosis, and for arterial and
venous thromboembolism. The interac-
tion of hyperhomocyst(e)inemia with
hypertension and smoking is strong,
and the combined effect is more than
multiplicative. The combined effect of
homocysteine and cholesterol is addi-
tive10.
Massy et al. were pioneers in the
study of homocysteine metabolism in
renal transplant patients, and they
found by stepwise discriminant analy-
sis and by logistic regression analysis
in 42 patients that homocysteine was
also a risk factor associated with car-
diovascular disease in this population13.
Total homocysteine is significantly
increased in renal transplant pa-
tients35,36,37,40,41,65 as compared to healthy
controls35,65 or a matched renal dys-
function group35,40,65.
Determinants of homocyst(e)ine
concentration in renal transplant pa-
tients are listed in table 2.
In 1996, Arnadottir et al. reported
that renal transplant recipients on
cyclosporine had significantly higher
plasma homocyst(e)inemia than those
not on cyclosporine (19.7 ± 7.6 vs. 16.2
± 4.8 mmol/l, mean ± S.D)35. But in
1998, they described no correlation be-
tween plasma homocyst(e)ine and
cyclosporine concentration or doses of
cyclosporine, prednisone, and azathio-
prine40. It is not known how cyclos-
porine could interfere in homocysteine
metabolism, but cyclosporine could be
a methyl donor, since during its hepatic
metabolism, hydroxylation and N-
demethylation are important reactions66.
Moreover, Ducloux et al reported that
patients with or without cyclosporine
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had similar plasma homocyst(e)ine con-
centrations36,37. Woodside et al found no
difference in homocysteinemia between
patients receiving cyclosporin (n = 39,
homocysteine 11.0 ± 1.5  mmol/l), and
patients receiving prednisolone + aza-
thioprine (n = 16, 10.8 ± 1.6 mmol/l,
mean ± S.D.), although there was a sig-
nificant correlation between homocys-
teine and serum cyclosporin concentra-
tion in the sub-group of patients receiv-
ing that immunosuppressive regimen (r
= 0.42, P < 0.05)67. Gilfix et al showed
a negative correlation of tHcy to
cyclosporine when using C2 levels
(level of cyclosporine measured in the
second hour after administration), but
which was consistent with the negative
correlation between creatinine concen-
tration and C268. In our previous study,
although tHcy was similar under the two
schemes of immunosuppressors, there
was a strong negative correlation be-
tween tHcy and the cyclosporine trough
level (r= -0.79 and p= 0.01)65. As yet,
we have not found a difference between
tHcy levels with or without cyclosporine
or an effect of cyclosporine trough level
on homocyst (e)inemia.
Azathioprine, another immunosup-
pressive drug, causes absolute or rela-
tive deficiency in folate and/or cobal-
amin, a condition also reported to in-
crease homocyst(e)inemia.
Födinger et al observed no effect of
azathioprine on homocysteine metabo-
lism39. In contrast, Mazouz et al con-
cluded that the addition of azathioprine
to the standard immunosuppressive
regimen further increased Hcy serum
levels in renal transplant recipients,
which could be mediated by absolute
or relative deficiency in folate69.
In adult male rats, mean plasma
homocysteine concentration after treat-
ment with cortisol was substantially
lower, compared with the level of
plasma homocysteine in the control
group, indicating a significant protec-
tive effect of steroid on plasma ho-
mocysteine levels 70.
We did not observe a correlation
between azathioprine or prednisone
doses and homocyst(e)inemia in either
of the recipient groups or between
cyclosporine doses in the group taking
cyclosporine.
It had been previously reported that
there was no difference in homocys-
teine levels between individuals treated
with tacrolimus and cyclosporine, and
there was no correlation between ho-
mocysteine and immunosuppressant
trough levels or the development of
histologically diagnosed chronic graft
nephropathy 71.
Although vitamin B6 treatment re-
sulted in a 22.1% reduction in geomet-
ric-mean post-methionine-loading in-
creases in plasma total homocysteine
levels, and folic acid plus vitamin B12
treatment caused a 26.2% reduction in
geometric-mean fasting plasma total
homocysteine levels15, their effect on
cardiovascular disease is not known.
We must stress that hyperho-
mocyst(e)inemia is an important prob-
lem in the follow-up of renal trans-
plant recipients. Renal recipients with
renal function loss and the older re-
cipients are the most at risk popula-
tion. Since hyperhomocyst(e)inemia
increases  cardiovascular disease risk
and patient survival, efforts have to be
made to search for other possible de-
terminants of homocyst(e)inemia and
to reduce it.
Table 2 - Determinants of homocyst(e)in concentration in renal transplant patients.
Reference Hyperhomocyst(e)inemia µmol/l Determinants
Arnadottir et al.19 27.7 ± 14.8** glomerular filtration rate, creatinine concentration, plasma folate level
Ducloux et al.6 21.4 ± 10.2** glomerular filtration rate, creatinine concentration, plasma folate level
Ducloux et al.5 21.3 ± 9.7** glomerular filtration rate, plasma folate level
Arnadottir et al.4 19.0 ± 6.9** glomerular filtration rate, cyclosporine-treated group, sex, plasma folate
level
Machado et al.20 18.4 ± 9.6* glomerular filtration rate, creatinine concentration
Machado et al. – this paper 18.0 ± 8.2* creatinine concentration, age, weight
Boston et al.22 15.6** creatinine concentration, age, pyridoxal 5‘-phosphate level, plasma
folate level, plasma vitamin B12 level
Födinger et al.15 17.6 ± 9.2** glomerular filtration rate, plasma folate level, MTHFR genotype , sex,
body index mass, age and plasma vitamin B12 level
* - serum level
** - plasma level
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RESUMO RHCFAP/3019
MACHADO DJ de B e col. - Hiper-
homocisteinemia em transplantados
renais crônicos. Rev. Hosp. Clín.
Fac. Med. S. Paulo 55(5):161-168,
2000.
Objetivos: A hiper-homocistei-
nemia é um fator de risco importante
para aterosclerose e, esta é uma das
principais causas de óbito em trans-
plantados renais. O objetivo deste es-
tudo é avaliar a influência da terapêu-
tica imunossupressora na homocis-
teinemia de receptores de transplante
renal.
Casuística e Método: Vinte e nove
pacientes foram divididos em dois gru-
pos: grupo I (n=20) – pacientes trans-
plantados renais em uso de ciclos-
porina, azatioprina e prednisona; gru-
po II (n=9) – pacientes transplantados
renais em uso de azatioprina e
prednisona; grupo III (n=7) doadores
de rim para pacientes dos grupos I e II,
constituíram o grupo controle. O nível
sérico de creatinina e o clearance esti-
mado de creatinina, o nível sérico de
ciclosporina, o perfil de lipídeos, a con-
centração de ácido fólico e vitamina
B12 e as características clínicas dos in-
divíduos foram avaliados na procura de
determinantes da homocisteinemia. A
concentração sérica de homocisteína
foi medida através da cromatografia de
alta resolução e a concentração de áci-
do fólico e vitamina B12 por radio-
imunoensaio.
Resultados: Os pacientes tinham
48.8 ± 15.1 aa e 43.3 ± 11.3 aa respec-
tivamente, nos grupos I e II e os doa-
dores 46.5 ± 14.8 aa. A homo-
cisteinemia sérica média dos pacientes
transplantados renais foi de 18.07 ±
8.29 mmol/l. No grupo de pacientes
em uso de ciclosporina foi de 16.55 ±
5.6 mmol/l e no grupo sem ciclos-
porina foi de 21.44 ± 12.1 mmol/l
(NS). No grupo de doadores foi signi-
ficativamente menor (9.07 ± 3.06
mmol/l; grupo I + grupo II vs. grupo
III, p<0.008), não tendo sido encontra-
do nenhum caso de hiper-homocis-
teinemia. Houve correlação entre ida-
de (r=0.427; p<0.005), peso corpóreo
(r=0.412; p<0.05), creatinina sérica
(r=0.427; p<0.05), clearance estimado
de creatinina (r=0.316; p<0.10) e tHcy
nos pacientes transplantados renais.
Porém no modelo de regressão múlti-
pla, só foram significativos idade (co-
eficiente = 0.253; p=0.009) e creatinina
sérica (coeficiente =8.07; p=0.045). No
grupo de transplantados renais encon-
tramos 38% de casos com hiper-
homocist(e)inemia sendo sete casos
(35%) do grupo I e quatro casos (45%)
do grupo II, baseado nos níveis séricos
normais.
Conclusões: Os pacientes trans-
plantados renais apresentam hiper-
homocisteinemia independente do es-
quema de imunossupressão que este-
jam utilizando. A hiper-homocisteine-
mia após o transplante renal tem como
determinantes a idade do receptor e o
seu nível de creatinina sérica.
DESCRITORES: Homocisteína.
Transplante renal. Ciclosporina.
Azatioprina. Prednisona.
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